The Relevance of the RELEVANCE Trial in Follicular Lymphoma
Rituximab/lenalidomide is not superior to rituximab/chemotherapy for initial treatment of advanced‑stage follicular lymphoma, with similar toxicity and progression‑free survival.
This finding informs clinicians that the less toxic, chemo‑free regimen of rituximab plus lenalidomide does not provide clinically meaningful advantages over standard rituximab‑based chemotherapy in newly diagnosed follicular lymphoma, thereby guiding treatment choice and resource allocation.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience